Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16765836 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3HSD11B1MAPT | |
| SCHEMBL15245656 | 0.82 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL16765658 | 0.73 | — | — | |
| SCHEMBL2885558 | 0.73 | ALDH1A1 (0.45) | HSD11B1KDM4EPOLBL3MBTL1 | |
| SCHEMBL2888368 | 0.73 | ALDH1A1 (0.45) | HSD11B1KDM4EPOLBL3MBTL1 | |
| SCHEMBL2885555 | 0.73 | ALDH1A1 (0.45) | HSD11B1KDM4EPOLBL3MBTL1 | |
| SCHEMBL2885557 | 0.73 | ALDH1A1 (0.45) | HSD11B1KDM4EPOLBL3MBTL1 | |
| SCHEMBL4484271 | 0.70 | — | — | |
| SCHEMBL19733325 | 0.65 | ALDH1A1 (0.40) | CHRM2CHRM1CHRM3MAPT | |
| SCHEMBL19713060 | 0.65 | ALDH1A1 (0.40) | CHRM2CHRM1CHRM3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2800748-B1 | CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2017-03-29 | — | — | EP | disclosed |
| US-9453014-B2 | Cyclic amide derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase and uses thereof | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2016-09-27 | — | — | US | disclosed |
| US-20150158860-A1 | CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158860-A1 | CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF | HSD11B1, HSD11B2, HSD17B1 | CHRM2 3800/4885CHRM1 3710/4885CHRM3 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.